Clarity Pharmaceuticals Valuation Multiples

Clarity Pharmaceuticals Overview

About Clarity Pharmaceuticals

Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.

Founded

2010

HQ

Employees

N/A

Website

claritypharmaceuticals.com

Sectors

BiopharmaceuticalsBioTechHealthTech

Financials (LTM)

Revenue: $4M

EBITDA: ($66M)

EV

$709M

Valuation Multiples

Multiples.vc

Start free trial

Clarity Pharmaceuticals Financials

Clarity Pharmaceuticals reported last 12-month revenue of $4M and negative EBITDA of ($66M).

In the same LTM period, Clarity Pharmaceuticals generated ($66M) in EBITDA losses and had net loss of ($66M).

Clarity Pharmaceuticals P&L

In the most recent fiscal year, Clarity Pharmaceuticals reported revenue of — and net income of —.

Clarity Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Clarity Pharmaceuticals Stock Performance

Clarity Pharmaceuticals has current market cap of $863M, and enterprise value of $709M.

Clarity Pharmaceuticals' stock price is $2.32.

Clarity Pharmaceuticals Valuation Multiples

Clarity Pharmaceuticals trades at 188.5x EV/Revenue multiple, and (10.8x) EV/EBITDA.

Clarity Pharmaceuticals Financial Valuation Multiples

As of April 1, 2026, Clarity Pharmaceuticals has market cap of $863M and EV of $709M.

Equity research analysts estimate Clarity Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Clarity Pharmaceuticals has a P/E ratio of (13.1x).

Clarity Pharmaceuticals Margins & Growth Rates

Clarity Pharmaceuticals' revenue in the last 12 month grew by 108%.

Clarity Pharmaceuticals' rule of 40 is (1194%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Clarity Pharmaceuticals' rule of X is (1141%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Clarity Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Clarity Pharmaceuticals M&A Activity

Clarity Pharmaceuticals acquired XXX companies to date.

Last acquisition by Clarity Pharmaceuticals was on XXXXXXXX, XXXXX. Clarity Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Clarity Pharmaceuticals Investment Activity

Clarity Pharmaceuticals invested in XXX companies to date.

Clarity Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Clarity Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).